BERLIN, May 2, 2006-Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending that the European Commission grants an extension of the indication for Betaferon® (interferon beta-1b) to add the treatment of the first clinical event suggestive of multiple sclerosis (MS) to its existing indications. A decision by the European Commission is expected by summer 2006.

The CHMP decision is based on impressive results from the international BENEFIT* study which showed that Betaferon® 250 mcg treatment in the early phase of the disease reduced the risk of developing clinically definite MS (CDMS) by 50 percent compared with placebo.1,2 Furthermore, patients in the Betaferon® group were two times better protected3 against developing MS as defined by the McDonald diagnostic criteria.4 The BENEFIT study is the first study in such patients with a high-dose, high-frequency interferon beta-1b.

“The results from the BENEFIT trial show that Betaferon consistently reduced the risk of relapse when used in newly emerging MS, providing the best chance of long-term efficacy to patients with multiple sclerosis and to people who are at risk of developing MS,” said Darlene Jody, MD, Head of Schering Group's Specialized Therapeutics Global Business Unit. “The CHMP decision represents a significant milestone, highlighting the importance of treating patients early on – even before MS is clinically definite – to provide rapid, early control of progression to clinically definite MS.”